Non-alcoholic steatohepatitis (NASH) is an aggressive form of non-alcoholic fatty liver disease (NAFLD) that may progress to cirrhosis and hepatocelluar carcinoma (HCC), and so far, there is limited FDA approved therapies for NASH. Animal models of NAFLD/NASH are crucial for preclinical evaluation of efficacy and safety. Given the rapidly growing recognition that NAFLD/NASH is the hepatic manifestation of metabolic syndrome, scientists are paying a lot more attention to the metabolic characteristics of NASH animal models they choose to work with. Among most classical NASH animal models, the long duration of diet treatment or the lack of metabolic phenotypes limits their application in candidate drug screening. To fill the gap, GemPharmatech developed a rapid NASH model based on Alms1 mutant mice (B6-Alms1-del mice). B6-Alms1-del mice develop a plethora of early onset metabolic phenotypes on chow diet, such as obesity, hyperglycemia, hyperlipidemia and fatty liver. To verify the applicability of this Alms1 NASH model in preclinical research, the promising preclinical drug Semaglutide was used to treat Alms1-del NASH mice.